ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 840

Fibromyalgia, Somatic Symptoms, and Mental Illness In View Of The 2013 Diagnostic and Statistical Manual Of Mental Disorders

Frederick Wolfe1, Brian T. Walitt2, Robert S. Katz3 and Winfried Häuser4, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Rheumatology, Washington Hospital Center, Washington, DC, 3Rush Medical College, Chicago, IL, 4Klinikum Saarbrücken, Saarbrücken, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fibromyalgia and psychological status

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pain research conceptualizes fibromyalgia (FM) as a Physical or Somatic Symptom Disorder (PSD or SSD). However, the 2013 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) identifies an SSD mental disorder (DSM-SSD) when there are findings of “positive symptoms (distressing somatic symptoms + excessive thoughts, feelings, and behaviors in response to these symptoms),” whether or not the symptoms are “medically explained.” FM is defined on the basis of somatic symptoms and concerns arose that DSM criteria would turn FM into a mental disease. We examined DSM mental illness in patients with rheumatoid arthritis (RA), including those with FM. We utilized RA patients to provide a large subject base and appropriate control subjects, and to avoid self-selection for severity.

Methods: We used the Patient Health Questionnaire-15 (PHQ-15), a validated assessment of somatic symptom severity, to operationalize the DMS-5 SSD definition. For mental illness Definition 1 a DSM-SSD positive individual had to have at least 2 “severe” symptoms (“bothered a lot”) and a total PHQ-15 somatic symptom severity classification of “medium” (10-14) or “high” (>=15). A second, more restrictive definition (Definition 2) required the total PHQ-15 symptom severity classification to be high (>=15). We diagnosed FM according to the survey modified 2010 FM criteria.

Results: Of the 4718 RA patients, 22.1% were definition 1 DSM-SSD positive and 6.7% definition 2 positive (Table 1). When FM (+) patients were considered, 68.8% and 28.8% satisfied mental illness 1 and 2 definitions. 19.8% of RA patients also satisfied ACR2010 criteria. The probability of satisfying the mental illness definitions increased as a function of polysymptomatic distress (fibromyalgianess) (Figure 1). Persons who met either definition had more abnormal scores for all severity and outcome measures, including functional status, pain, quality of life, household income, etc.

Conclusion: There are serious problems of face validity when mental illness is defined on the basis of “excessive thoughts, feelings, and behaviors” in response to somatic symptoms, as somatic symptoms form the basis of rheumatic diseases. In addition, somatic symptoms increase in number and severity with increasing pain, and no clear direction of causality can be discerned. If somatic symptoms are to be expected in rheumatic diseases, then it all comes down to “excessive”, a term that cannot be reliably or validity defined. The high rates mental illness identified by the DSM-SSD definition in our study suggest the mental illness classification is invalid.

 

FM (-)

(80.2 %)

FM (+)

(19.8 %)

All

Mental illness 1 (%)

10.7

68.8

22.1

Mental illness 2 (%)

1.2

28.8

6.7

PHQ-15

5.6

12.3

6.9

Polysymptomatic distress

63.0

19.3

8.7

entalillness.jpg

 


Disclosure:

F. Wolfe,
None;

B. T. Walitt,
None;

R. S. Katz,
None;

W. Häuser,

Pfizer Inc,

5,

Daiichi Pharmaceutical Corporation,

5,

Abbott Laboratories,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibromyalgia-somatic-symptoms-and-mental-illness-in-view-of-the-2013-diagnostic-and-statistical-manual-of-mental-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology